Spyre Therapeutics Inc
SYREHealthcare|Biotechnology|USA
$97.74
-1.01 (-1.02%)
Tangible Book
$6.53
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07012395 A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | Ulcerative Colitis, Inflammatory Bowel Diseases | P2 | Recruiting | 645 | RCT, Double-blind | SPY001, SPY002, SPY003 |
| NCT07148414 A Study of SPY072 in Rheumatic Disease | Rheumatoid Arthritis, Psoriatic Arthritis | P2 | Active | 285 | RCT, Double-blind | SPY002-072, Placebo |
| NCT06873724 A Study of SPY003-207 in Healthy Volunteers | Healthy | P1 | Active | 59 | RCT, Double-blind | SPY003-207 |
| NCT06622070 A Study of SPY002-072 in Healthy Volunteers | Healthy | P1 | Recruiting | 56 | RCT, Double-blind | SPY002-072 |
| NCT06672718 A Study of SPY002-091 in Healthy Volunteers | Healthy | P1 | Active | 50 | RCT, Double-blind | SPY002-091 |
| NCT07652294 Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD | Ulcerative Colitis, Inflammatory Bowel Diseases | P2 | By Invite | 645 | Double-blind | SPY001, SPY002, SPY003 |
| NCT06448247 A Study of SPY001-001 in Healthy Volunteers | Healthy | P1 | Completed | 96 | RCT, Double-blind | SPY001-001 |